PH1
Clinical trials for PH1 explained in plain language.
Never miss a new study
Get alerted when new PH1 trials appear
Sign up with your email to follow new studies for PH1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a single gene edit stop kidney stones at the source?
Cure Recruiting nowThis early-stage trial is testing an experimental gene editing therapy called YOLT-203 in people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes the liver to produce too much oxalate, leading to recurrent kidney stones and potential kidney failure. T…
Matched conditions: PH1
Phase 1 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug, YOLT-203, in 36 children and adults with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The goal is to see if a single dose can safely lower oxalate levels in urine and blood…
Matched conditions: PH1
Phase 2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC